Blog

Monoclonal antibodies represent an important class of therapies for an ever-increasing number of diseases, infections, and health conditions. That’s why scientists around the world are working to improve the processes required to engineer new antibody candidates for therapeutic use. The…

Since the start of the COVID-19 pandemic, the Codex DNA team has been working hard to ensure that our customers have access to the tools they need to help in the fight against this public health scourge. We currently offer…

Today, in our ongoing employee profile series, we catch up with a member of our R&D team. Team member: Krishna Kannan, Staff Scientist Came aboard: November 2019 What do you do at Codex DNA? As part of the R&D team,…

As we are quickly approaching the end of 2020, we’re taking a moment to look back at the year — all 237 months of it. While we hope to never go through another year like this one, we can’t help…

At a recent Oxford Global NextGen Omics UK congress, our own Kirsty Maclean gave a presentation about how the BioXp™ system is powering advances in cell engineering. While she started with a high-level view of how synthetic biology applies to…

You probably know Codex DNA as the developer of the world’s first and only automated benchtop solution for generating gene fragments, clones, and libraries. While we’re incredibly proud of what we’ve accomplished so far, our mission goes well beyond streamlining…

There’s celebrating in the halls — and virtual halls — of Codex DNA. We are truly honored that our new BioXp™ 3250 system was selected as one of the year’s best innovations by The Scientist. This is a very prestigious…

One of the most popular applications of synthetic biology is to confer desired traits to an organism. Designing a range of possibilities and then testing each one for fitness, productivity, stability, or some other goal is critically important as the…

Back in 2013, I played a small role in response to what then seemed like the next potential pandemic — an outbreak of H7N9, an avian influenza virus. At the time, I was working with Novartis scientists, and we were…

If you were there for the early days of synthetic biology, you probably remember it the way we do: a relatively small number of academic scientists toiling in labs to build key parts, like toggle switches, and tinkering with the…

In the age of COVID-19, there has been a ton of scientific interest in nanobodies, or single-domain antibodies that can be used for finely targeted viral vaccines. It’s also been a hot topic among users of our BioXp™ system —…

Without question, the global outbreak of the novel coronavirus 2019 (SARS-CoV-2) that causes COVID-19 has dominated scientific discussion and has been fodder for a wealth of publications as the world urgently races for a better understanding of the mechanism of…

Breast cancer is now recognized as the most common malignancy worldwide among women, irrespective of age. Today’s standard of care and breast cancer management relies heavily on chemotherapy, hormone therapy, and targeted therapy. However, there is still much to be…

The Codex DNA team really enjoyed attending this year’s virtual Global Synthetic Biology Conference hosted by SynBioBeta. If you missed the event, we’ve got you covered — here’s our take on highlights from the meeting. BioXp™ system in the spotlight…

We’re continuing our blog series, looking at the DNA of Codex DNA — our incredible employees and their stories. Team member: Katie Lyons, Senior Scientist Came aboard: 2008 What do you do at Codex DNA? I develop and adapt biological…

For cancer patients with few other treatment options, the need for new targeted immunotherapies is genuinely a matter of life or death. So how to accelerate the development of new therapies? One key component is automated DNA synthesis. That was…

The treatment landscape for lymphoma – especially aggressive B-cell lymphomas — has been transformed by adoptive cellular immunotherapy with chimeric antigen receptor (CAR) T cells. Clinical trials with a focus on anti-CD19 CAR-T cell therapy have shown efficacy and long-term…

For BioXp™ system users, antibody drug discovery is one of the most popular applications. That’s why we were delighted to participate in the recent Oxford Global Biologics virtual conference, with a presentation from our own Kirsty Maclean, Director of Applications…

Several recent publications from the rockstar team at GigaGen illustrate how they are using the BioXp™ system to streamline antibody drug discovery workflows. It’s tough to overstate the importance of this area of research: monoclonal antibodies, antibody drug conjugates, and…

Today we’re excited to launch a blog series focused on our most valuable resource: our people. We wouldn’t be where we are today — enabling the tremendous science done by our customers — without the Codex DNA family. We’ll be…

Please join us in welcoming the newest member of the Codex DNA family. Like its BioXp™ 3200 predecessor, the BioXp™ 3250 system is a fully automated, benchtop platform for synthetic biology workflows — but this one reduces the timelines for…

When it comes to improving life, there is no science more exciting than synthetic biology. The more we learn from reading the DNA or RNA code of every organism on this planet, the better equipped we are to make significant…